Kaltreider H B, Barth E, Pellegrini C
Exp Lung Res. 1981 Aug;2(3):231-8. doi: 10.3109/01902148109052318.
Effector cells of both T-lymphocyte-mediated and B-lymphocyte-mediated immunity can be induced experimentally to appear in the lung. It is not known whether such effector lymphocytes arise from precursor cells resident in the lung or if they are recruited from systemic sources. Previous studies demonstrated that IV administration of sheep erythrocytes to dogs consistently resulted in the appearance of specific antibody-forming cells, B-cell effectors, in lavage preparations obtained from the lung. In the present study, experiments were performed to determine the mechanism of appearance of effector B-cells in the lung after IV immunization. Control, sham-operated, and splenectomized dogs were immunized IV with 10(10) sheep erythrocytes. The concentrations of antibody-forming cells appearing in lymphocytes obtained from the lung and from peripheral blood were measured during both the primary and the secondary immune responses. Control and sham-operated dogs developed high concentrations of antibody-forming cells in blood 5 days after immunization, but splenectomized dogs did not. Antibody-forming cells consistently appeared in substantial numbers in lymphocytes obtained by lavage from lungs of control and sham-operated animals, however, they failed to appear in lungs of animals which had undergone splenectomy. Similar results were obtained both after primary and after secondary IV immunization. The data indicate that in this model, namely after IV immunization, with sheep erythrocytes, pulmonary antibody-forming cells or their precursors are derived from systemic sources (spleen) via the circulating blood. The observations provide strong in vivo evidence that lung antibody-forming cells are not generated locally after IV priming and boosting. The results of the present study relate directly to the mechanism of appearance of antibody-forming cells in lungs after IV, not local immunization. The study defines and documents one mechanism by which immune effector cells can appear in lung tissue.
T淋巴细胞介导的免疫和B淋巴细胞介导的免疫效应细胞都可以通过实验诱导出现在肺部。目前尚不清楚这些效应淋巴细胞是源自肺部驻留的前体细胞，还是从全身来源募集而来。先前的研究表明，给狗静脉注射绵羊红细胞会持续导致在从肺部获得的灌洗制剂中出现特异性抗体形成细胞，即B细胞效应细胞。在本研究中，进行了实验以确定静脉免疫后肺部效应B细胞出现的机制。对对照犬、假手术犬和脾切除犬静脉注射10¹⁰个绵羊红细胞进行免疫。在初次和二次免疫反应期间，测量从肺部和外周血获得的淋巴细胞中出现的抗体形成细胞的浓度。对照犬和假手术犬在免疫后5天血液中出现高浓度的抗体形成细胞，但脾切除犬则未出现。通过灌洗从对照动物和假手术动物的肺部获得的淋巴细胞中始终大量出现抗体形成细胞，然而，在脾切除动物的肺部未出现。初次和二次静脉免疫后均获得了类似的结果。数据表明，在该模型中，即静脉注射绵羊红细胞免疫后，肺部抗体形成细胞或其前体通过循环血液源自全身来源（脾脏）。这些观察结果提供了强有力的体内证据，表明静脉注射启动和加强免疫后肺部抗体形成细胞不是在局部产生的。本研究结果直接涉及静脉注射而非局部免疫后肺部抗体形成细胞出现的机制。该研究定义并记录了免疫效应细胞可以出现在肺组织中的一种机制。
